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sychiatryArchival Report BPThe Effects of Antipsychotic Treatment on
Presynaptic Dopamine Synthesis Capacity in
First-Episode Psychosis: A Positron Emission
Tomography Study
Sameer Jauhar, Mattia Veronese, Matthew M. Nour, Maria Rogdaki, Pamela Hathway,
Sridhar Natesan, Federico Turkheimer, James Stone, Alice Egerton, Philip McGuire,
Shitij Kapur, and Oliver D. HowesISSABSTRACT
BACKGROUND: Elevated striatal dopamine synthesis capacity has been implicated in the etiology and antipsychotic
response in psychotic illness. The effects of antipsychotic medication on dopamine synthesis capacity are poorly
understood, and no prospective studies have examined this question in a solely ﬁrst-episode psychosis sample.
Furthermore, it is unknown whether antipsychotic efﬁcacy is linked to reductions in dopamine synthesis capacity.
We conducted a prospective [18F]-dihydroxyphenyl-L-alanine positron emission tomography study in antipsychotic
naïve/free people with ﬁrst-episode psychosis commencing antipsychotic treatment.
METHODS: Dopamine synthesis capacity (indexed as inﬂux rate constant) and clinical symptoms (measured using
Positive and Negative Syndrome Scale) were measured before and after at least 5 weeks of antipsychotic treatment in
people with ﬁrst-episode psychosis. Data from a prior study indicated that a sample size of 13 would have .80%
power to detect a statistically signiﬁcant change in dopamine synthesis capacity at alpha = .05 (two tailed).
RESULTS: A total of 20 people took part in the study, 17 of whom were concordant with antipsychotic medication at
therapeutic doses. There was no signiﬁcant effect of treatment on dopamine synthesis capacity in the whole striatum
(p = .47), thalamus, or midbrain, nor was there any signiﬁcant relationship between change in dopamine synthesis
capacity and change in positive (r = .35, p = .13), negative, or total psychotic symptoms.
CONCLUSIONS: Dopamine synthesis capacity is unaltered by antipsychotic treatment, and therapeutic effects are
not mediated by changes in this aspect of dopaminergic function.
Keywords: Antipsychotic drugs, Dopamine, F-DOPA, Positron emission tomography, Psychosis, Schizophrenia
https://doi.org/10.1016/j.biopsych.2018.07.003Psychotic disorders such as schizophrenia have a lifetime
prevalence of more than 1% and are a major cause of disease
burden in young adults (1). Antipsychotic medications (dopa-
mine D2/3 receptor antagonists) are the mainstay of treatment for
acute psychosis and reduce risk of relapse in the longer term (2).
Antipsychotics, however, have limited efﬁcacy in a substantial
proportion of patients from illness onset (3–5). The use of anti-
psychotics is also limited by poor tolerability (6). Thus, there is a
need to understand the neurobiology underlying treatment
response to guide development of alternative treatments (7).
The dopamine hypothesis is one of the leading neurobio-
logical hypotheses of psychosis (8–11). A meta-analysis of
imaging studies found that the predominant dopamine abnor-
malities seen in schizophrenia involve the presynaptic dopa-
mine system, including elevated striatal dopamine synthesis
capacity (indexed as inﬂux rate constant [Kicer]), using [18F]-
dihydroxyphenyl-L-alanine ([18F]-DOPA) positron emissionª 2018 Society o
N: 0006-3223tomography (PET) (12). Moreover, striatal dopamine synthesis
capacity increases longitudinally with onset of psychosis (13),
and striatal dopamine release is greater in patients who are
acutely unwell relative to stable patients (14). Added to cross-
sectional studies in which dopamine synthesis capacity has
been related to psychotic symptoms (15,16), this suggests
dopamine function to have a state component in psychosis.
Consistent with these ﬁndings and the dopamine hypothe-
sis, all antipsychotic drugs are dopamine D2/3 receptor
blockers (17–19). Antipsychotic drugs may also act presyn-
aptically to reduce dopamine neuron ﬁring, and this could be
their primary mode of therapeutic action (20). Support for this
comes from rodent studies, which have shown that subchronic
treatment with haloperidol and a number of other ﬁrst-
generation antipsychotics, as well as second-generation anti-
psychotics, induces depolarization blockade of dopamine
neurons (20,21). Prolonged treatment leads to decreased ﬁringf Biological Psychiatry. This is an open access article under the
CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Psychiatryof dopamine neurons in substantia nigra and ventral tegmental
area (22). The effects of antipsychotics on dopamine neuron
ﬁring have also been tested in a neurodevelopmental animal
model of schizophrenia (the methylazoxymethanol acetate
model) that shows increased population activity of midbrain
dopamine neurons. This study showed that depolarization
blockade is induced more rapidly in these animals than in wild-
type animals (23), suggesting that depolarization blockade may
be more rapid in a hyperdopaminergic state. This contrasts
with ﬁndings from an animal study using microdialysis, which
showed no effect of chronic haloperidol treatment on striatal
levels of extracellular dopamine and its metabolites (24).
To date, only one study has examined effects of subchronic
antipsychotic treatment in people with psychosis. Gründer
et al. found decreased [18F]-DOPA uptake (k3) in striatum and
thalamus in 9 antipsychotic-free people with schizophrenia
treated with haloperidol (25). That study also found that greater
improvement in negative symptoms, but not positive symp-
toms, was associated with greater reduction in thalamic
[18F]-DOPA uptake. This suggests that reduction in dopamine
synthesis capacity may be related to symptom change. How-
ever, the study by Gründer et al. used haloperidol, a ﬁrst-
generation antipsychotic, at relatively high doses (mean dose
of 8.9 mg/day)—a dose that would be expected to result in D2/3
occupancy .90% in ﬁrst-episode patients (17), which might
explain effects on the dopamine system. Modern clinical
practice, however, involves treatment with second-generation
antipsychotics at lower relative doses, which would be ex-
pected to have lower D2/3 occupancy (26). It therefore remains
unknown whether antipsychotic treatment with second-
generation antipsychotics at doses reﬂecting current practice
decreases striatal dopamine synthesis capacity and whether
this has any relationship to symptom change.
Therefore, we sought to examine the effect of antipsychotic
medication on striatal dopamine synthesis capacity in people
experiencing their ﬁrst episode of psychotic illness and its
relationship to symptom change.
We tested the following hypotheses: 1) There would be a
decrease in striatal dopamine synthesis capacity with anti-
psychotic treatment; and 2) Reduction in striatal dopamine
synthesis capacity would be directly associated with reduction
in positive psychotic symptoms, and reduction in thalamic
dopamine synthesis capacity would be directly associated
with negative psychotic symptom change.
An exploratory analysis of associative striatum baseline Kicer
and symptomatic response was also conducted based on a
prior cross-sectional study suggesting a relationship between
this striatal subdivision and antipsychotic response (27).
METHODS AND MATERIALS
Ethical permission was obtained from the East of England–
Cambridge East Ethics Committee and the Administration of
Radioactive Substances Advisory Committee. All participants
provided informed written consent to participate.
Participants
Patients were recruited from ﬁrst-episode psychosis services
in London. Inclusion criteria were diagnosis of a psychotic
disorder according to ICD-10 criteria (28), fulﬁlling criteria for2 Biological Psychiatry - -, 2018; -:-–- www.sobp.org/journalhaving a ﬁrst episode of psychosis (29), requiring treatment
with antipsychotic medication, and being antipsychotic naïve
or antipsychotic free for at least 6 weeks [other clinical studies
in similar populations require being antipsychotic free for a
minimum of 3 weeks (30,31)].
For comparison, a matched sample of healthy control
subjects was included. Inclusion criteria included no psychi-
atric morbidity, as assessed by the Mini-International Neuro-
psychiatric Interview (32), and no contraindications to PET
scanning, as per the patient sample.
Exclusion criteria for all subjects were history of signiﬁcant
head trauma, dependence on illicit substances or alcohol,
medical comorbidity (other than minor illnesses), use of
sodium valproate [owing to effects on dopamine synthesis
capacity (33)], and contraindications to scanning (such as
pregnancy).
Tobacco smoking was not an exclusion criterion.
Clinical Measures
The following clinical measures were rated at baseline and at
least 5 weeks after antipsychotic initiation: Positive and
Negative Syndrome Scale (PANSS) (34), Global Assessment of
Functioning (35), and Clinical Global Impression–Improvement
scale (CGI-I) (36). Response status (dichotomized as
responder vs. nonresponder) was measured, in keeping with
prior PET studies, based on a rating of much improved or very
much improved on CGI-I (17).
Baseline
People presenting with ﬁrst-episode psychosis received one
baseline [18F]-DOPA scan prior to initiation of antipsychotic
medication. They were classiﬁed as antipsychotic naïve or
medication free (free of oral antipsychotic medication for 6
weeks or longer).
Treatment
Because this was a naturalistic study, antipsychotic treatment
was decided by the treating clinician and patient. All doses
were required to be within the therapeutic range for the drug
deﬁned in the Maudsley Prescribing Guidelines (36). Use of
other psychotropic medication (such as antidepressants and
benzodiazepines) was permitted, although use of sodium val-
proate was not [because it may have effects on [18F]-DOPA
uptake (33)]. To assess concordance with antipsychotic
medication, we used a multisource approach, requiring evi-
dence of adequate adherence on at least two of the following:
antipsychotic plasma levels, pharmacy and electronic medical
dispensing records, and report from the patient and an inde-
pendent source (family member/caregiver or health care pro-
fessional). Adequate concordance was deﬁned as taking a
minimum of 80% of prescribed doses, in line with consensus
recommendations (37). To measure antipsychotic exposure,
we determined chlorpromazine-equivalent dose years, calcu-
lated as described by Andreasen et al. (38). [In the cases of
lurasidone and amisulpride, we used the method described by
Leucht et al. (39), using data from the Maudsley Prescribing
Guidelines, because these are not covered by Andreasen
et al.].
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All participants received follow-up [18F]-DOPA scans and
clinical measures (PANSS, Global Assessment of Functioning,
and CGI-I) after at least 5 weeks of antipsychotic treatment at
an adequate dose as deﬁned in the Maudsley Prescribing
Guidelines and meeting concordance criteria described above.
Clinical follow-up was conducted 6 months after the base-
line scan to conﬁrm diagnosis using the Mini-International
Neuropsychiatric Interview.
[18F]-DOPA PET Imaging
All participants were asked not to eat or drink (except water)
and to refrain from alcohol for 12 hours prior to scan. Cigarette
smokers were not permitted to smoke during the 4 hours
preceding the scan. The 4-hour cutoff for last cigarette smoked
in this study was based on evidence that nicotine’s occupancy
of the acetylcholine nicotinic receptor does not change
appreciably between 2 and 5 hours after last administration of
nicotine (40).
Imaging data were obtained on a Siemens Biograph 6
HiRez PET scanner (Siemens, Erlangen, Germany) in three-
dimensional mode. One hour before scanning, participants
received 400 mg of entacapone, a peripheral catechol-o-
methyl-transferase inhibitor, and 150 mg of carbidopa, a
peripheral aromatic acid decarboxylase inhibitor, to prevent
formation of radiolabeled metabolites that may cross the
blood-brain barrier (41). Participants were positioned in the
scanner with the orbitomeatal line parallel to the transaxial
plane of the tomograph. Head position was marked and
monitored, and movement was minimized using a head strap.
After acquiring a computed tomography scan for attenuation
correction, [18F]-DOPA was administered by bolus intravenous
injection 30 seconds after start of PET imaging. PET data were
acquired in 32 frames of increasing duration over the 95-
minute scan (frame intervals: 8 3 15 seconds, 3 3 60 sec-
onds, 5 3 120 seconds, 16 3 300 seconds).
The region-of-interest analysis was conducted blind to medi-
cation status. Our primary end point was striatal inﬂux constant
(Kicer) for the whole striatum. For each participant, we calculated
Kicer for bilateral whole striatum, caudate, putamen, and thalamus
in light of prior work by Gründer et al. (25). Whole striatum was
chosen instead of striatal functional subdivisions (such as asso-
ciative striatum) given lack of prior investigation of striatal sub-
divisions and antipsychotic effects. Secondary analyses were
also conducted with substantia nigra, given prior ﬁndings of a
relationship between psychotic symptoms and dopamine syn-
thesis capacity in substantia nigra (15), and with associative
striatum and treatment response, based on prior literature (27).
Correction for head movement during scan was performed
by employing a mutual information algorithm (42). SPM8 (43)
was used to automatically normalize a tracer-speciﬁc [18F]-
DOPA template (44) together with the striatal brain atlas as
deﬁned by Martinez et al. (45) and the Hammersmith brain atlas
(46). The Hammersmith brain atlas was used to identify
extrastriatal regions and reference region (cerebellum). The
region-of-interest atlas was transformed into the subject’s PET
space using the tracer-speciﬁc template without using cor-
egistered magnetic resonance imaging. This method showed
good reliability in a previous test–retest study (47).BKicer was calculated using the Patlak–Gjedde graphical
approach adapted for a reference tissue input function (48).
Further details of the image analysis approach are given in
prior publications (16,49). Although our reference region
approach is robust to global differences in radiotracer delivery
to the brain (50,51), we examined the reference region (cere-
bellum) to ascertain change in standardized uptake value in
cerebellum at 95 minutes. To exclude potential effects of
weight, we conducted correlation analysis of weight and Kicer
for participants at baseline.
Striatal volume measures were derived from the atlas-based
segmentation as the number of voxels in the striatal region
multiplied by the volume of a single PET image voxel (voxel
volume = 2.05 mm 3 2.05 mm 3 2 mm = 8.41 mm3). This
analysis was undertaken to investigate whether there was a
change in striatal volume over time.Statistical Analysis
Statistical analyses were performed using SPSS Version 23
(IBM Corp., Armonk, NY), and signiﬁcance was set at p , .05
(two tailed). Normality of distribution for dopamine synthesis
capacity (Kicer), PANSS ratings, and changes in all these
measures was assessed using the Shapiro-Wilk test. To test
hypothesis 1 (change in Kicer with antipsychotic medication)
and changes in clinical variables over follow-up, we used
paired sample t tests. The data from Gründer et al. (25) indi-
cated that a sample size of 13 would have .80% power to
detect a statistically signiﬁcant change in dopamine synthesis
capacity at alpha = .05 (two tailed).
To test hypothesis 2 (relationship betweenchange inKicer and
change in PANSS symptoms scores), we used Pearson’s cor-
relation coefﬁcients for normally distributed data and Spear-
man’s correlation coefﬁcients for non-normally distributed data.
Because hypothesis 2 related to the relationship between
dopamine synthesis capacity and symptom change irrespective
of treatment (examining possible state effects), all subjects who
took part in the study were included (including those non-
concordant with antipsychotic medication and those receiving
inadequate antipsychotic treatment) in the primary analysis. We
then conducted a further exploratory analysis to determine
whether correlations between dopamine synthesis capacity and
symptom change were seen in patients who met full adherence
criteria to test speciﬁcity to antipsychotic treatment.
Change in clinical symptom scales was measured by
calculating percentage change in PANSS score, accounting for
minimum scores (7 for positive and negative symptoms and
30 for total symptoms) as shown here for the PANSS positive
symptom subscale:
% change in positive PANSS ¼
ððbaseline score27Þ 2 ðfollow-up score 2 7ÞÞ  100
ðbaseline score 2 7Þ
Change in dopamine synthesis capacity (DSC) was calculated
as follows:
Change in DSC ¼ DSCbaseline2 DSCfollow-up
DSCbaseline
 100iological Psychiatry - -, 2018; -:-–- www.sobp.org/journal 3
Effects of Antipsychotics on Dopamine Function in Psychosis
Biological
PsychiatryRESULTS
A total of 20 patients completed the study and received two
[18F]-DOPA scans. Of these, 15 were antipsychotic naïve and 5
were medication free at time of scanning (previously receiving
antipsychotic medication and being medication free for 6
weeks or longer). Of these patients, 3 did not meet the criteria
for adequate treatment prior to the follow-up scan (1 patient
was treated with a subtherapeutic dose of antipsychotic
medication because that patient declined to take higher doses,
and 2 patients were nonconcordant).
Therefore, we excluded these 3 patients, leaving 17 patients
to test hypothesis 1 (change in Kicer after antipsychotic
treatment).
All 20 patients were included to test hypothesis 2 (rela-
tionship between change in Kicer and change in symptoms)
because this was not dependent on antipsychotic treatment.
Demographic and clinical details are given in Table 1. Details of
antipsychotic treatment that patients received after baseline
scan are given in Supplemental Table S1.
Median time between scans was 71 days (interquartile
range of 125 days).
No relationship was found between time between PET
scans and change in Kicer (r = 2.03, p = .92).
Of the 20 patients recruited in total, 12 met criteria for
schizophrenia and 8 for bipolar affective disorder at 6-month
follow-up.
There was a statistically signiﬁcant elevation in whole
striatal Kicer in patients compared with control subjects (t38 =
2.32, p = .03, two tailed) (control subjects mean = 12.41 3
1023/min, SD = 1.1 3 1023/min).
Data on the baseline scans for 18 patients reported here
have been published in Jauhar et al. (16) and Jauhar et al.
(52). None of the follow-up scans have been previously
reported.
The latter study analyzed baseline Kicer in a larger group of
ﬁrst-episode psychosis patients (n = 26). The 8 additional
subjects did not receive follow-up F-DOPA PET scans.Antipsychotic Treatment
Two patients started on an antipsychotic but discontinued it
owing to side effects and switched to another antipsychotic
that they then received at an adequate dose and duration priorTable 1. Demographic and Medication Status for Both PET Sam
Variable
PET Sample Adherent
to Treatment (n = 17)
P
or
Age, Years, Mean (SD) 24.00 (2.87)
Male Subjects (%) n = 15 (88)
Ethnicity of Subjects (%) White, n = 6 (35)
Black, n = 5 (29)
Asian, n = 2 (12)
Mixed, n = 4 (24)
W
Bl
As
M
Smoking Status (%) Current smoker, n = 9 (53)
Past smoker, n = 3 (18)
Nonsmoker, n = 5 (29)
C
Pa
No
Medication Status at Baseline Antipsychotic naïve, n = 12
Antipsychotic free, n = 5
An
An
N/A, not applicable; PET, positron emission tomography.
4 Biological Psychiatry - -, 2018; -:-–- www.sobp.org/journalto follow-up scan. Where this occurred, the discontinued
medication is noted ﬁrst, followed by the drug they then
received. Three patients took low-dose aripiprazole to prevent
weight gain and hyperprolactinemia in addition to the main
antipsychotic. Where this occurred, the main antipsychotic is
noted ﬁrst, followed by aripiprazole to indicate its use as an
adjunct. Regarding adjunctive medication, 1 patient was taking
sertraline (150 mg) at initial scan, which was unchanged at
follow-up.
There was a signiﬁcant reduction in all symptoms following
treatment (Table 2).
Baseline Kicer and Change in PANSS
There was a signiﬁcant positive relationship between baseline
associative striatum Kicer and change in positive symptoms
(r = .52, p = .03).
There was a signiﬁcant positive relationship between
baseline associative striatum Kicer and change in total symp-
toms (r = .49, p = .045).
There was a trend for an association between whole
striatum Kicer and change in positive symptoms (r = .48,
p = .05).
There was no association between whole striatum Kicer and
change in total symptoms (r = .46, p = .06).
There was no association between whole striatum Kicer and
change in negative symptoms (Spearman’s r = .37, p = .14).
Change in Dopamine Synthesis Capacity With
Antipsychotic Medication
Median antipsychotic treatment received was 0.38 chlor-
promazine dose years (interquartile range of 0.41). There was
no signiﬁcant change in whole striatal dopamine synthesis
capacity (Kicer) in people who received adequate treatment
(baseline mean = 13.07 3 1023/min, SD = 1.01 3 1023/min;
follow-up mean = 12.85 3 1023/min, SD = 1.09 3 1023/min),
t16 = 0.74, p = .47 (Figure 1).
Data points for all subjects are given as a scatterplot in
Supplemental Figure S1, categorized as responders, non-
responders (using CGI-I), and subjects taking subtherapeutic
medication and those nonconcordant with antipsychotic
medication.
Because aripiprazole is a partial agonist, in contrast to a
full antagonist, and thus may have different effects, weples
ET Sample Including Nonadherent
Partially Adherent Patients (n = 20) Control Sample (n = 20)
24.55 (3.36) 24.55 (3.99)
n = 17 (85) n = 18 (90)
hite, n = 8 (40)
ack, n = 6 (30)
ian, n = 2 (10)
ixed, n = 4 (20)
White, n = 10 (50)
Black, n = 6 (30)
Asian, n = 1 (5)
Mixed, n = 3 (15)
urrent smoker, n = 10 (50)
st smoker, n = 3 (15)
nsmoker, n = 7 (35)
Current smoker, n = 8 (40)
Past smoker, n = 3 (15)
Nonsmoker, n = 9 (45)
tipsychotic naïve, n = 15
tipsychotic free, n = 5
N/A
Table 2. Clinical and Imaging Details
Variable PET Baseline, n = 17 PET Follow-up, n = 17 Difference Between Time Pointsa
Injected Activity, MBq 146.96 (4.33) 145.32 (4.41) Z = 20.024, p = .98
Speciﬁc Activity, GBq/mmol 0.031 (0.005) 0.027 (0.011) t16 = 1.47, p = .16
PANSS Positive 20.59 (6.98) 12.76 (5.02) Z = 23.27, p , .05
PANSS Negative 17.24 (5.22) 12.47 (5.34) Z = 23.00, p , .05
PANSS Total 77 (21) 47 (19.5) Z = 23.52, p , .05
Values are presented as median (interquartile range).
GBq, gigabecquerel; MBq, megabecquerel; PANSS, Positive and Negative Syndrome Scale.
aPaired t test used for normally distributed data; Wilcoxon signed ranks test used for non-normally distributed data.
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received aripiprazole monotherapy and repeated the anal-
ysis after excluding all subjects taking aripiprazole,
including those taking it as an adjunct to a dopamine
antagonist. There was no signiﬁcant effect of antipsychotic
treatment on Kicer after restricting the analyses to subjects
taking full antagonists in either analysis (p = .40 and p = .91,
respectively).
There was no signiﬁcant effect of treatment on Kicer for the
other regions analyzed (striatal functional subdivisions,
caudate, putamen, thalamus, and substantia nigra) (see
Table 3).
There was no change in standardized uptake value in the
reference region (cerebellum) with treatment (baseline mean =
1.3 3 1023/min, SD = 0.35 3 1023/min; follow-up mean =
1.45 3 1023/min, SD = 0.58 3 1023/min), t16 = 21.27, p = .15.
There was no change in striatal volume before and after anti-
psychotic treatment (baseline mean = 2006.53 mm, SD =
180.54) and follow-up (mean = 2047.94 mm, SD = 216.43),
t16 = 21.39, p = .18. There was no effect of weight on Ki
cer
(r = .08, p = .73).
Relationship Between Change in Dopamine
Synthesis Capacity and Symptom Change
There was no signiﬁcant correlation between percentage
decrease in whole striatal Kicer and percentage improvementBa
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Figure 1. Dopamine synthesis capacity at baseline and follow-up
showing group means and standard error of the mean. There was no sig-
niﬁcant change in dopamine synthesis capacity over time with antipsychotic
treatment (p = .47). Kicer, inﬂux rate constant.
Bin PANSS positive symptoms (n = 20, r = .35, p = .13), total
symptoms (r = .25, p = .29), or negative symptoms (r = .10,
p = .68) (see Figure 2).
There was no relationship between change in thalamic
Kicer and change in PANSS negative symptom severity
score in people taking antipsychotic treatment (n = 17,
r = 2.26, p = .31).
DISCUSSION
Our main ﬁndings were that there was no signiﬁcant change
in striatal dopamine synthesis capacity with antipsychotic
treatment and no signiﬁcant association between change in
dopamine synthesis capacity and change in psychotic symp-
toms. To the best of our knowledge, this is the ﬁrst study to
measure change in dopamine synthesis capacity after treat-
ment with second-generation antipsychotics.
Effects of Antipsychotic Medication on Presynaptic
Dopamine Function
Our ﬁnding of no change in presynaptic striatal dopamine
function with prolonged antipsychotic treatment is consistent
with acute studies in healthy volunteers, which found no sig-
niﬁcant overall change in dopamine synthesis capacity after
treatment with a number of different antipsychotic drugs
(53–55). However, our ﬁndings contrast with those in the only
other study examining effects in a markedly smaller sample of
people with schizophrenia (25), which found a decrease in
dopamine synthesis capacity in caudate and putamen after a
mean of 5 weeks haloperidol treatment. A possible explanation
could be the relatively high dose of haloperidol (nearly double
the chlorpromazine-equivalent dose in our study). Thus, taken
together with our ﬁndings, this suggests that while higher
doses of antipsychotics may have effects, antipsychotic
treatment at doses in the range typically used in current
practice is not associated with signiﬁcant changes in dopa-
mine synthesis capacity.
Our study differed from the Gründer et al. (25) study in terms
of experimental design and methodology for quantiﬁcation of
F-DOPA kinetics and therefore is not directly comparable.
From a methodological perspective, the two parameters of
interest (k3 in the Gründer et al. study and Kicer in our study) are
different. Kicer is related to k3 and Kicer in our study (56) but
also is dependent on perfusion and tissue-to-blood tracer
diffusion. One major methodological difference is the length of
scan (120 minutes in the Gründer et al. study vs. 95 minutes in
our study). There is evidence from monkey and human studies
that metabolism of radiolabeled dopamine becomesiological Psychiatry - -, 2018; -:-–- www.sobp.org/journal 5
Table 3. Mean Kicer in Striatal Subdivisions and Extra-striatal Regions Before and After Antipsychotic Treatment
Brain Region Kicer Baseline Kicer Follow-up p Value
Whole Striatum 13.07 3 1023 (1.01 3 1023) 12.94 3 1023 (0.79 3 1023) .47
Associative Striatum 13.04 3 1023 (1.07 3 1023) 12.87 3 1023 (0.86 3 1023) .59
Limbic Striatum 12.89 3 1023 (0.90 3 1023) 12.79 3 1023 (0.93 3 1023) .71
Sensorimotor Striatum 13.21 3 1023 (1.09 3 1023) 12.83 3 1023 (1.19 3 1023) .27
Caudate 11.12 3 1023 (0.93 3 1023) 11.93 3 1023 (1.10 3 1023) .51
Putamen 14.17 3 1023 (1.09 3 1023) 13.91 3 1023 (1.17 3 1023) .44
Thalamus 2.83 3 1023 (0.32 3 1023) 2.78 3 1023 (0.31 3 1023) .65
Substantia Nigra 7.21 3 1023 (0.81 3 1023) 7.06 3 1023 (1.12 3 1023) .55
Values are presented as mean (SD).
Kicer, inﬂux rate constant.
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metabolism is not accounted for in the analysis used by
Gründer et al. (25), this could introduce noise into the mea-
surement of k3.
It is also worth noting that Gründer et al. (25) found, after
haloperidol, an increase in absolute terms of radiolabeled
DOPA volume of distribution and reduction in radiolabeled
DOPA from striatal tissue back across the blood-brain barrier.
We did not measure these parameters, although we would
expect alterations in them to alter Kicer if antipsychotic treat-
ment had altered them in our study, so this is unlikely to explain
our ﬁndings.
Microdialysis ﬁndings show that antipsychotic treatment
acutely induces a transient increase in striatal extracellular
dopamine levels, which fall back to basal levels with chronic
treatment (24). Our results are consistent with these ﬁndings
and extend them to show that, in addition to having no lasting
effect on extracellular dopamine levels, chronic treatment does
not alter dopamine synthesis capacity. It should be recognized
that we did not measure dopamine neuron ﬁring, and so our
ﬁndings cannot exclude an effect on midbrain dopamine
neuron ﬁring, as seen in the electrophysiology studies of
chronic antipsychotic treatment (20). Determining this will
require preclinical studies to test the relationship among
dopamine neuron ﬁring, striatal dopamine levels, and dopa-
mine synthesis capacity.-20 -10 0 10 20
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Figure 2. Relationship between change in dopamine synthesis capacity
and percentage improvement in Positive and Negative Syndrome Scale
(PANSS) positive symptoms. There is no signiﬁcant correlation between
improvement in PANSS positive symptom improvement and change in inﬂux
rate constant (Kicer) (r = .35, p = .13).
6 Biological Psychiatry - -, 2018; -:-–- www.sobp.org/journalWe did not ﬁnd a change in striatal volume with antipsy-
chotics in our study. A systematic review of the effects of
second-generation antipsychotics, such as those used in our
study, found inconsistent effects on striatal volume, with some
studies reporting increases, others ﬁnding decreases, and
others ﬁnding no effects, as was the case in our study (59).
Limitations
Our study was powered to detect a statistically signiﬁcant
difference and relationship between change in symptoms and
change in dopamine synthesis capacity of the size reported by
Gründer et al. (25). While a type II error remains possible, the
data suggest that any effect is unlikely to be clinically signiﬁ-
cant. It should be acknowledged that the follow-up at 6
months showed that the patient group included patients who
subsequently met diagnostic criteria for bipolar affective dis-
order as well as schizophrenia. It is often not possible to
disentangle diagnoses at baseline, although we should
emphasize that criteria for study entry included the presence of
psychosis, according to criteria used before to deﬁne psy-
chosis in ﬁrst-episode illness (60) and requiring antipsychotic
treatment (61).
Because our study was naturalistic in design, we were un-
able to test the effects of one speciﬁc antipsychotic and
accept that some antipsychotics used in this study (e.g.,
amisulpride) have more selectivity for D2/3 receptors. None-
theless, by focusing on antipsychotic response and including
only people taking antipsychotics at a dose that would block
D2/3 receptors, we examined a potential common mechanism
by which antipsychotics might act.
It should be noted that 4 hours after smoking a cigarette
could correspond to the period of subjective nicotine with-
drawal, although nicotine’s occupancy of nicotinic receptors in
the brain remains high (40).
It is conceivable that antipsychotics could have had an ef-
fect on blood ﬂow (62) and effects on tracer delivery to the
reference region (cerebellum). Our ﬁnding of no difference in
standardized uptake value in the cerebellum suggests that this
is not a signiﬁcant issue, although further studies are required
to exclude this and investigate local blood ﬂow changes.
Moreover, it is unlikely to account for our ﬁndings given that
this would require opposite blood ﬂow effects in the cere-
bellum to the striatum to account for no overall change. Ideally,
tests of the biological effect of antipsychotic drugs would
involve randomizing patients to placebo treatment as well as
Effects of Antipsychotics on Dopamine Function in Psychosis
Biological
Psychiatryexcluding nonspeciﬁc effects of treatment. This would have
ethical implications and therefore is unlikely to be feasible.
Implications for Clinical Care
Our main ﬁnding, that antipsychotics do not alter dopamine
synthesis capacity in people presenting with ﬁrst-episode
psychosis, extends cross-sectional evidence that dopamine
synthesis capacity remains elevated, even in patients on long-
term antipsychotic treatment (12,63), to indicate that antipsy-
chotics do not normalize the major (presynaptic) dopaminergic
abnormality seen in the disorder. This provides a potential
neurobiological explanation for why psychosis recurs after
antipsychotic treatment is stopped (64) and, potentially for
continued treatment, suggests that stopping dopamine re-
ceptor blockade would lead to dopamine dysfunction’s being
unmasked.
In conclusion, antipsychotic medication does not alter
dopamine synthesis capacity in people with ﬁrst-episode
psychosis, and change in symptoms is not associated with
change in dopamine synthesis capacity. This indicates that
therapeutic effects of antipsychotic medication are not due to
altering dopamine synthesis capacity.
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